The Medical Letter on Drugs and Therapeutics
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ceftolozane/tazobactam (Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and intra-abdominal infections in adults.

MECHANISM OF ACTION — Like other cephalosporins, ceftolozane inhibits bacterial cell-wall synthesis. Ceftolozane's structure is similar to that of the third-generation cephalosporin ceftazidime, but it has a modified side-chain that increases its activity against Pseudomonas aeruginosa.1 Tazobactam inhibits most class A and some class C beta-lactamases, which extends ceftolozane’s activity to include most extended-spectrum beta-lactamase (ESBL)-producing gram-negative organisms and adds some anaerobic activity.1,2


The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ceftolozane Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
Article code: 1463b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian